A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Abstract
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov numb …
Keywords
canada
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
covid-19
sars-cov-2
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
adult
female
male
N.I.H.
Extramural
middle aged
Randomized Controlled Trial
Double-Blind Method
Multicenter Study
United States
pneumonia
betacoronavirus
occupational exposure
coronavirus infections / prevention & control*
pandemics / prevention & control*
viral / prevention & control*
treatment failure
hydroxychloroquine / therapeutic use*
pmid:32492293
pmc7289276
doi:10.1056/nejmoa2016638
david r boulware
matthew f pullen
kathy h hullsiek
hydroxychloroquine / adverse effects
inhalation exposure
post-exposure prophylaxis*
Access
Citation
ID:
274346
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
274346
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet